Answers are grounded in this paper and cite their sources.
Evaluates walking’s effect on pain in early breast cancer, suggesting reevaluation of intervention dosage.
To the Editor, We read with interest the WISE trial by Guth and colleagues, which examined whether a 24-week home-based walking program could prevent aromatase inhibitor (AI)-induced arthralgia in patients with early breast cancer [1]. The authors achieved excellent recruitment and adherence, and the intervention group walked significantly more steps than the control group. However, two points not discussed in the paper may help interpret the null finding.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: